What were the actual revenue and earnings figures versus analysts' expectations? | CRL (Aug 06, 2025) | Candlesense
CRL

What were the actual revenue and earnings figures versus analysts' expectations?

Answer

The brief excerpt you provided does not contain the specific financial numbers needed to answer the question. It only includes the headline, the source, and the publication date:

  • Title: “Charles River Laboratories Announces Second‑Quarter 2025 Results”
  • Source: Business Wire (Wilmington, Mass.)
  • Date: 2025‑08‑06 11:00 UTC

There is no mention of the actual revenue, earnings per share (EPS), or the analysts’ consensus estimates within the text you shared. Consequently, I can’t compare the company’s reported results to what analysts were expecting.

What to do next

To obtain the figures you’re looking for, you’ll need to locate the full press release or a more detailed news article that includes:

  1. Actual Q2 2025 results – total revenue, net income, and earnings per share (or adjusted EPS) that Charles River Laboratories reported.
  2. Analysts’ expectations – the consensus forecast for revenue and EPS that Wall Street analysts had published before the release (often reported as “forecast” or “estimate” in earnings coverage).

Typical sources for this information are:

  • The complete Charles River Laboratories (CRL) earnings press release on the company’s investor‑relations website.
  • A financial news article (e.g., Bloomberg, Reuters, Yahoo! Finance) that usually includes a “vs. consensus estimate” table.
  • An analyst consensus summary from data providers such as FactSet, Thomson Reuters, or S&P Capital IQ, which aggregates analysts’ forecasts.

If you can provide the full press release or a more detailed news snippet, I’ll be able to extract the actual revenue and earnings figures and directly compare them to the analysts’ expectations. Until then, the answer cannot be completed with the current information.

Other Questions About This News

Are there any notable changes in the customer pipeline, such as new large contracts or lost contracts? Did the company provide any revised guidance for FY2025 or FY2026? Did the management comment on any strategic initiatives (e.g., acquisitions, R&D investments, partnership expansions) that could influence long‑term performance? Did the release mention any impacts from recent regulatory or political developments that could affect the business? How did the profit margins compare to prior quarters and to peers in the life‑science services sector? How is the company's cash flow and balance‑sheet strength positioned for potential reinvestment or capital returns? How might this earnings result affect the stock’s short‑term trajectory and trading volume? What is the outlook for pricing pressure or cost inflation in the company's operating environment? What trends emerged in each business segment (e.g., drug development, safety assessment, regulatory services) and how might they affect future growth?